RAG-1 Inhibitors
RAG-1 inhibitors comprise a diverse group of chemicals that indirectly modulate the activity of the Recombination Activating Gene 1 (RAG-1) protein by targeting signaling pathways critical for immune responses. Tofacitinib, Ibrutinib, and Ruxolitinib act on the JAK-STAT signaling pathway, which is intricately connected to processes regulated by RAG-1. These inhibitors interfere with cellular processes involved in immune responses, impacting RAG-1-mediated pathways and contributing to the inhibition of RAG-1 function in specific cellular contexts.
Similarly, Baricitinib, Acalabrutinib, and Fedratinib, through their effects on JAKs and BTK, indirectly influence RAG-1 by disrupting signaling cascades related to B-cell development. Dasatinib, TAK-242, VX-745, TPCA-1, SB 203580, and Bay 11-7082 target various signaling pathways, such as p38 MAP kinase and NF-κB, that intersect with RAG-1-mediated processes. The broad spectrum of these inhibitors allows for the modulation of immune responses and RAG-1 function in specific cellular contexts. In summary, RAG-1 inhibitors offer a range of options to researchers studying immune-related processes, providing insights into dysregulated immune responses. The detailed understanding of their biochemical interactions emphasizes their significance in elucidating the complexities of immune regulation and the role of RAG-1 in these intricate cellular pathways.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that disrupts B-cell receptor signaling. As B-cell development involves processes regulated by RAG-1, inhibiting BTK with Ibrutinib can indirectly influence RAG-1-mediated pathways, impacting the development and function of B-cells. The disruption of B-cell receptor signaling contributes to the modulation of RAG-1 function in specific cellular contexts. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib is a JAK1 and JAK2 inhibitor that affects the JAK-STAT signaling pathway. Similar to Tofacitinib, Ruxolitinib indirectly influences cellular processes related to immune responses, potentially intersecting with RAG-1-mediated pathways. The modulation of JAK-STAT signaling contributes to the inhibition of RAG-1 function in specific cellular contexts. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $196.00 $651.00 | ||
Baricitinib is a JAK1 and JAK2 inhibitor, impacting the JAK-STAT signaling pathway. By inhibiting JAKs, Baricitinib indirectly modulates cellular processes involved in immune responses, potentially influencing pathways that intersect with RAG-1-mediated processes. The modulation of immune signaling pathways contributes to the inhibition of RAG-1 function in specific cellular contexts. | ||||||
Acalabrutinib | 1420477-60-6 | sc-507392 | 250 mg | $255.00 | ||
Acalabrutinib is a second-generation Bruton's tyrosine kinase (BTK) inhibitor that interferes with B-cell receptor signaling. As B-cell development involves processes regulated by RAG-1, inhibiting BTK with Acalabrutinib can indirectly influence RAG-1-mediated pathways, impacting the development and function of B-cells. | ||||||
TG101348 | 936091-26-8 | sc-364740 sc-364740A | 5 mg 25 mg | $207.00 $515.00 | 6 | |
Fedratinib (TG101348) is a JAK2 inhibitor, affecting the JAK-STAT signaling pathway. Similarly to Ruxolitinib, Fedratinib indirectly influences cellular processes related to immune responses, potentially intersecting with RAG-1-mediated pathways. The modulation of JAK-STAT signaling contributes to the inhibition of RAG-1 function in specific cellular contexts. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a multitargeted kinase inhibitor that affects various tyrosine kinases. By inhibiting multiple kinases, Dasatinib can indirectly modulate signaling pathways related to immune responses, potentially intersecting with RAG-1-mediated processes. The broad spectrum of kinase inhibition contributes to the modulation of RAG-1 function in specific cellular contexts. | ||||||
Resatorvid | 243984-11-4 | sc-476758 | 5 mg | $360.00 | ||
TAK-242 (Resatorvid) is an inhibitor of Toll-like receptor 4 (TLR4) signaling, impacting the TLR signaling pathway. TLRs play a role in immune responses, and inhibiting TLR4 with TAK-242 can indirectly influence pathways intersecting with RAG-1-mediated processes. The disruption of TLR4 signaling contributes to the modulation of RAG-1 function in specific cellular contexts. | ||||||
VX 745 | 209410-46-8 | sc-361401 sc-361401A | 10 mg 50 mg | $183.00 $842.00 | 4 | |
VX-745 is an inhibitor of p38 MAP kinase, affecting the p38 MAP kinase signaling pathway. By inhibiting p38 MAP kinase, VX-745 can indirectly modulate cellular processes related to immune responses, potentially intersecting with RAG-1-mediated processes. The modulation of p38 MAP kinase signaling contributes to the inhibition of RAG-1 function in specific cellular contexts. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $130.00 | 12 | |
TPCA-1 (IKK-2 Inhibitor IV), affecting the NF-κB signaling pathway. By inhibiting IKK-2, TPCA-1 can indirectly modulate cellular processes related to immune responses, potentially intersecting with RAG-1-mediated processes. The modulation of NF-κB signaling contributes to the inhibition of RAG-1 function in specific cellular contexts. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a selective inhibitor of p38 MAP kinase, impacting the p38 MAP kinase signaling pathway. By inhibiting p38 MAP kinase, SB 203580 can indirectly modulate cellular processes related to immune responses, potentially intersecting with RAG-1-mediated processes. The modulation of p38 MAP kinase signaling contributes to the inhibition of RAG-1 function in specific cellular contexts. | ||||||